I find it reassuring that NPAT is about $1.8 to 2 millions, inclusive of medical innovation unit. I think in the past CMP occasionally excludes medical innovation unit cost, making it slightly confusing to analyze its profitability, after all cost and R&D.
Overall, the revenue has grown 10% pcp, likely to continue its trajectory. Current P/E is about 27.
The share price is fairly valued. Need to see eHealth and spin-off to support further increase in valuation.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $53.82M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.0¢ | 28.0¢ | $410 | 1.464K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 20999 | 1 |
View Market Depth
| Last trade - 10.17am 18/07/2025 (20 minute delay) ? |
| CMP (ASX) Chart |